212 related articles for article (PubMed ID: 34697897)
1. GDF15 expression in glioma is associated with malignant progression, immune microenvironment, and serves as a prognostic factor.
Guo L; Chen Y; Hu S; Gao L; Tang N; Liu R; Qin Y; Ren C; Du S
CNS Neurosci Ther; 2022 Jan; 28(1):158-171. PubMed ID: 34697897
[TBL] [Abstract][Full Text] [Related]
2. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
3. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
4. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
5. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
6. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
7. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
8. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
10.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
11. DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway.
Su X; Liu J; Tu Z; Ji Q; Li J; Liu F
Transl Cancer Res; 2024 Apr; 13(4):1786-1806. PubMed ID: 38737693
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
13. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma.
Wang H; Wang X; Xu L; Zhang J
Cancer Med; 2023 Feb; 12(4):4951-4967. PubMed ID: 36043552
[TBL] [Abstract][Full Text] [Related]
14. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.
Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
[TBL] [Abstract][Full Text] [Related]
15. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment.
Ning W; Qiu Z; Ji X; Wang X; An Y; Wang S; Zhang H
J Mol Neurosci; 2020 Oct; 70(10):1501-1511. PubMed ID: 32495005
[TBL] [Abstract][Full Text] [Related]
17. BACH1 as a potential target for immunotherapy in glioblastomas.
Yuan F; Cong Z; Cai X; Zhu J; Yuan L; Wang Y; Tang C; Ma C
Int Immunopharmacol; 2022 Feb; 103():108451. PubMed ID: 34923423
[TBL] [Abstract][Full Text] [Related]
18. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
19. An integrative multi-omics analysis based on liquid-liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature.
Zheng J; Wu Z; Qiu Y; Wang X; Jiang X
J Transl Med; 2022 Jan; 20(1):55. PubMed ID: 35093128
[TBL] [Abstract][Full Text] [Related]
20. An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.
Tang G; Peng J; Huo L; Yin W
BMC Bioinformatics; 2023 Jun; 24(1):225. PubMed ID: 37264314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
